ICD and CRT-D Indicated Patients
Conditions
Keywords
implantable cardioverter defibrillator (ICD), defibrillation leads, cardiac resynchronization therapy (CRT)
Brief summary
The purpose of this study is to evaluate and document appropriate clinical performance of the new 4-SITE Header / Lead interface in the TELIGEN 100 HE 4-SITE (VR and DR) implantable cardioverter defibrillator (ICD) PGs (Models F103; F111), the COGNIS 100 HE 4-SITE cardiac resynchronization therapy ICD (CRT-D) PG (Model P108) when connected to any of the RELIANCE Quadripolar (4-SITE) defibrillation leads. Appropriate clinical performance of system components of the 4-SITE systems other than the new 4-SITE header / lead interface has been evaluated and documented already in the previously conducted COGNIS and TELIGEN 100 HE FIELD FOLLOWING STUDY, The COGENT-4 Field Following Study. Data collected may be used to support international regulatory submissions including the FDA and the Japanese Ministry of Health, Labour and Welfare.
Detailed description
The following devices will be used (all are CE-marked): * TELIGEN 100 HE 4-SITE (Single and Dual Chamber ICD) * Model Number: F103 (Quadripolar, VR); * Model Number: F111 (Quadripolar, IS-1, DR) * COGNIS 100 HE 4-SITE (CRT-D) o Model Number: P108 (Quadripolar, IS-1, IS-1) * RELIANCE 4-SITE leads (12 different model numbers in total as shown in the table below)
Interventions
None listed
Sponsors
Guidant Corporation
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Study Specific: * ICD / CRT-D Indication according to normal clinical practice * Patients receiving: * a single or dual chamber 4-SITE compatible ICD * or a 4-SITE compatible CRT-D * one of the RELIANCE 4-SITE defibrillation leads * Patients currently implanted with a pacemaker * upgraded to a 4-SITE compatible ICD or CRT-D (4-SITE header) * one of the RELIANCE 4-SITE defibrillation leads General: * Willing and capable of providing informed consent for * undergoing a 4-SITE system implant, * participating in all testing associated with this clinical investigation at an approved clinical investigational centre and at the intervals defined by this protocol * Geographically stable patients who are available for follow-up at a study centre * Age 18 or above, or of legal age to give informed consent specific to national law
Exclusion criteria
Study Specific: * ICD and CRT-D Patients scheduled for a device replacement * CRM Patients who have or who would need an lead adaptor * All patients who have an active or non-active defibrillation lead other than 4-SITE General: * Not willing and not capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation (including VT/VF shock conversion) at an approved clinical investigational centre and at the intervals defined by this protocol * Patients who were in NYHA Class IV during the last 3 month * Patients with pre-existing diseases, which may confound study results * Patients currently requiring dialysis, * Cancer patients * Patients with drug and/or alcohol abuse history * Life expectancy \< 12 months (or expected heart transplant within 12 months) * Patients on a Heart Transplant List * Women who are pregnant or plan to become pregnant. Method of assessment per physician discretion. * Enrolled in any other concurrent study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Appropriate Detection of induced VT | At Implant or during VT/VF testing up to one month after implant | Induced mean VT/VF detection time \< 4.5 seconds |
| Appropriate induced VT/VF Shock Conversion | At Implant or during testing within one month after implant | Successful VT/VF conversions (with 41 J, no external shock) will be 93% or higher |
| Appropriate pacing thresholds at follow-up with the 4-SITE defibrillation leads | entire duration of the study | Mean pacing threshold post implant ≤ 1.5V |
| Appropriate Lead Impedances as a measure of lead integrity over 12 month time | entire study duration | * Shocking lead impedance should be within the range of 20 and 80 OHM * Pace /sense lead impedance within 200 and 2000 OHM |
| Appropriate sensing and absence of artefacts | entire duration of study | Appropriate sensing and absence of artefacts during standardized pocket manipulations and standardized provocative maneuvers during FU |
Countries
Germany
Outcome results
None listed